Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 317-321

  Salfinger, Max ^b   Migliori, Giovanni Battista ^a  

^a IRCCS   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CROSS RESISTANCE; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; HEALTH CARE AVAILABILITY; HUMAN; LICENSING; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PROTOCOL COMPLIANCE; REVIEW; RISK ASSESSMENT; ANTIBIOTIC RESISTANCE; GENETICS; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; DRUG RESISTANCE, BACTERIAL; HUMANS; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84922112383     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00199814     Document Type: Review

References (27)

1. World Health Organization. Global tuberculosis report 2014. Document WHO/HTM/TB/2014.08. Geneva, World Health Organization, 2014.
2. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42:252-271.
3. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012;40:143-151.
4. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014;43:554-565.
5. Sotgiu G, Migliori GB. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther 2014 [In press DOI: 10.1016/j.pupt.2014.04.006].
6. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Document WHO/HTM/TB/2014.11. Geneva, World Health Organization, 2014.
7. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012;9:e1001300.
8. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013;42:156-168.
9. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013;42:169-179.
10. Brigden G, Nyang'wa BT, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2014;92:68-74.
11. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227.
12. Petrella S, Cambau E, Chauffeur A, et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006;50:2853-2856.
13. Cox EM. FDA accelerated approval letter to Janssen Research and Development (21CFR314.500). www.accessdata.fda.gov/drugsatfda-docs/appletter/2012/204384Orig1s0 00ltr.pdf
14. Centers for Disease Control and Prevention. Provisional CDC Guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR 2013;62:1-12.
15. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Document WHO/HTM/TB/2013.6. Geneva, World Health Organization, 2013.
16. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430-1442.
17. Migliori GB, Sotgiu G. Treatment of tuberculosis: have we turned the corner? Lancet 2012;380:955-957.
18. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-2981.
19. Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014;9:e102135.
20. Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015;45:554-557.
21. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014;43:289-292.
22. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014;44:1412-1417.
23. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449-1453.
24. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013;42:1614-1621.
25. Akkerman OW, van Altena R, Klinkenberg T, et al. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J 2013;42:1750-1752.
26. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013;42:785-801.
27. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014;43:1410-1420.